YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

In a phase 1 trial, a gene-editing therapy that targets ANGPTL3 was associated with few serious adverse events and at higher ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

Researchers report early but encouraging results on an experimental gene-editing treatment for high cholesterol.

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

Researchers in Australia have led a first-in-human trial for a breakthrough gene-editing therapy that halves bad cholesterol ...

CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company pioneering a novel gene editing platform to overcome drug resistance in solid tumors, today announced the publication of a ...

Researchers have found a new way to reactivate fetal hemoglobin without the need for gene-editing therapy, according to a new study.

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...